Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest advanced cancer Stories

2014-04-02 08:32:57

--First-in-Class CLIA Assay for Detection of Tumor-Specific Gene Amplifications Using Circulating Cell-Free DNA-- BALTIMORE, April 2, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analyses, today announced the launch of its METDetect(TM) Assay for the detection of MET gene amplifications in the circulation of cancer patients. Amplifications and other structural changes of the MET cancer gene have been associated with resistance to...

2014-02-19 16:24:15

--New Publication in Science Translational Medicine Confirms Utility of Cell-Free Circulating Tumor DNA (ctDNA) for Cancer Drug Development and Diagnosis-- BALTIMORE, Md., Feb. 19, 2014 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, reported that its proprietary technology was used in a major new study being published today in the journal Science Translational Medicine. The study, "Detection of...

2014-01-18 12:20:20

SAN FRANCISCO, Jan. 18, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) presented favorable data today from a Phase 1 study of etirinotecan pegol (EP, NKTR-102) in combination with 5-fluorouracil (5-FU)/Leucovorin (LV) in patients with advanced cancer. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated...

2013-10-15 04:21:08

CAMBRIDGE, England, October 15, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515 significantly reduced the symptoms of dry mouth (the primary endpoint) compared to placebo. APD515 is an optimised oromucosal (liquid) formulation of a currently...

2013-01-07 14:54:23

Blueprint could help guide treatment for patients who have exhausted all other options Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, is now offering patients with advanced cancer a cutting-edge clinical test that will provide them with a unique blueprint of their cancer genes. The new clinical test, known as CancerCode-45TM, evaluates an individual's tumor for genetic alterations in a select group of 45 genes and gives physicians the...

2012-10-03 10:24:26

AUSTIN, Texas, Oct. 3, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia drug Xilonix. The Company's groundbreaking therapeutic antibody was shown in a previous clinical study at MD Anderson Cancer Center in Texas to stop or reverse cachexia in about a third of all advanced cancer patients treated. Anti-tumor and anti-cachexia effects were seen in many different types of...

2012-05-14 02:28:11

INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 - 5, 2012. Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. The company remains committed to evaluating each of its molecules for biomarkers or genetic...

2012-02-14 11:40:16

The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to...

2012-02-14 08:00:00

DENVER, Feb. 14, 2012 /PRNewswire/ -- The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood...

2011-08-26 11:06:01

A new scoring system can more reliably predict whether patients with advanced cancer are likely to survive for "days", "weeks" or "months" finds a study published on bmj.com today. Patients with advanced cancer and their carers often wish to know how long they have left to live. This information is also important for clinicians to help them plan appropriate care. Clinician predictions of survival are the mainstay of current practice, but are unreliable, over-optimistic and subjective....